iSpecimen Inc. Reveals New Underwritten Offering Details
iSpecimen Inc. (Nasdaq: ISPC), a leading global marketplace that connects scientists with healthcare specimen providers, has recently shared an exciting development regarding its financial operations. The company has announced the pricing of a public offering that includes approximately 5,714,283 shares of its common stock. Priced at $0.70 per share, this underwritten offering is projected to generate around $4 million in gross proceeds for the company.
Intended Use of Proceeds
The funds raised from this offering will be strategically allocated to enhance various aspects of iSpecimen's operations. Specifically, $1.5 million is earmarked for marketing and advertising services through a partnership with IR Agency LLC. Furthermore, $1 million will go towards fulfilling a milestone payment to Sales Stack Solutions Corp., while the remainder of the proceeds will be utilized for general corporate purposes and working capital needs. This strategic allocation underscores the company's commitment to growth and expansion in the biospecimen marketplace.
Completion of the Offering
Expected to close shortly, this offering is dependent upon the satisfaction of customary closing conditions. WestPark Capital, Inc. has played a vital role in this process, acting as the Sole Book-Runner on the transaction, which enhances credibility and investor confidence in the offering.
Ensured Compliance with Regulations
This offering follows a registration statement that was recently declared effective by the Securities and Exchange Commission (SEC). Conducted on a firm commitment basis, it demonstrates iSpecimen's adherence to regulatory standards, ensuring that the offering aligns with legal requirements aimed at protecting investors.
About iSpecimen Inc.
In an era where medical research relies heavily on access to biological specimens, iSpecimen (Nasdaq: ISPC) positions itself as a bridge between researchers and the necessary biospecimens. The company's innovative, cloud-based platform empowers scientists from private and non-profit sectors to conveniently search for required biological samples from a robust partner network that includes hospitals, laboratories, biobanks, and blood centers.
Innovation in Biospecimen Provisioning
By leveraging advanced technology, iSpecimen simplifies and accelerates the process of specimen acquisition for researchers, ultimately aiding in the advancement of medical discoveries. As the need for access to such resources grows, iSpecimen's role becomes increasingly pivotal in the landscape of healthcare and scientific research.
Contact and Additional Information
For interested parties seeking more information, a final prospectus will soon be filed with the SEC, detailing the specifics of the offering. The prospectus will also be accessible through WestPark Capital, Inc.
For any inquiries, including investor relations, please feel free to reach out:
Investor Contact
KCSA Strategic Communications
Phil Carlson
Email: iSpecimen@kcsa.com
Frequently Asked Questions
What is the main purpose of the offering announced by iSpecimen Inc.?
The primary goal of the offering is to raise funds for marketing, operational activities, and general corporate purposes to aid in the company’s growth.
How much money is iSpecimen aiming to raise from this offering?
iSpecimen is looking to raise approximately $4 million from this public offering.
Who is handling the offering for iSpecimen?
WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering, ensuring the process is managed efficiently and effectively.
How will iSpecimen utilize the funds raised?
The raised funds will be allocated towards marketing services, a milestone payment to Sales Stack Solutions, and for general corporate operations.
Where can one find more information about the offering?
Additional details can be accessed in the final prospectus to be filed with the SEC or by contacting KCSA Strategic Communications for inquiries.
